Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
Asset
(322)
News
(154)
SEC filing
(82)
Event
(36)
Filter by content year
(-)
2022
(594)
Filter by form group
Filter by category
Filter by category
Search
News
Pfizer und BioNTech treiben COVID-19-Impfstoffstrategie weiter voran: neue klinische Studie mit Impfstoffkandidaten der nächsten Generation mit verbessertem Design des Spike-Proteins begonnen
News
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
SEC Filings
Form 6-K
Asset
ADR Example Form (GER only)
ADR Example Form (GER only)
19.3 KB
Asset
20220722 BioNTech Weekly Buyback Report EN
20220722 BioNTech Weekly Buyback Report EN
3.3 MB
Asset
20220729 BioNTech Weekly Buyback Report EN
20220729 BioNTech Weekly Buyback Report EN
3.6 MB
Asset
20220722 BioNTech Weekly Buyback Report DE
20220722 BioNTech Weekly Buyback Report DE
3.3 MB
Asset
20220729 BioNTech Weekly Buyback Report DE
20220729 BioNTech Weekly Buyback Report DE
3.6 MB
News
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
News
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
Pagination
Previous page
‹‹
Page 2
Next page
››